NCT06578234RecruitingPhase 4
Hyperemic mYocardial Perfusion by adEnosine at diffeRent Doses
Source: ClinicalTrials.gov · Last updated 13 Aug 2026
Brief summary (registry, in English)
Adenosine is a commonly used pharmaceutical stressor at cardiac magnetic resonance examinations to assess suspected chronic coronary syndrome (CCS). However, several studies have reported that the current use of adenosine does not induce adequate hyperemic response in a substantial number of patients, leading to false diagnostics. The aim of this trial is to investigate the hyperemic effect of the standard dose of adenosine (140 microgram/kg/min) to the high dose of adenosine (210 microgram/kg/min) to improve the diagnostic methods using adenosine as a stressor and ultimately improve treatment decisions and patient prognosis in CCS.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- First submitted
- 15 Aug 2024
- Start date
- 23 Oct 2024
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Region Skane
- Diseases
- Coronary artery disease
- NCT number
- NCT06578234
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 180
- From 23 Oct 2024 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with medication containing dipyradimol or teofyllamin/teofyllin
- Devices contraindicated to CMR imaging (pacemaker, implants, intracranial clips etc)
- Cardiovascular medication
- Medication that might influence cardiovascular health
Other illness
- Severe or decompensated heart failure
- Asthma or severe chronic obstructive pulmonary disease
- Known allergy or adverse reaction to adenosine or mannitol
- Known allergy or adverse reaction to gadolinium contrast agents
- Known systemic disease
- Known cardiac disease
Lab values
- Known chronic renal failure (eGFR \<45mL/min/1.73m2)
Other
- Patients:
- Acute referral (in-house patients)
- Clinically unstable
- Acute chest pain
- Non sinus rhythm (e.g. atrial fibrillation)
- AV-block II or III
- Left Bundle Branch Block
- Systolic blood pressure \<90 mmHg or \>230 mmHg at rest
- Increased intracranial pressure
- Claustrophobia
- Pregnancy or breast feeding (screened by question only)
- Inability to give informed consent due to mental state, language difficulties etc
- Healthy volunteers:
- Any of the exclusion criteria for patients
- Blood pressure \> 140/90 measured according to clinical routine
- Smoking
Who the study is looking for
- Patients:
- The subject has given their written consent to participate in the trial.
- Are referred to Department of Clinical Physiology, Skåne University Hospital, for suspected or known CCS or heart failure
- Matches the inclusion criteria for sex and age (6 females and 6 males from each group in each age decade from 40 to \>80 years old)
- Matches the inclusion criteria for no known heart failure (group b) or known heart failure (group c)
- No caffein intake \<24h prior to the examination
- Healthy volunteers:
- The subject has given their written consent to participate in the trial.
- Matches the inclusion criteria for sex and age (6 females and 6 males from each group in each age decade from 40 to \>80 years old)
- No caffein intake \<24h prior to the examination
Age in the registry: 40 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinical Physiology, Department of Clinical Sciences Lund, Lund University, Skåne University Hospital Coordinator of this site? Confirm its status | Lund | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.